Overview
- Metsera accepted Pfizer's revised cash‑plus‑CVR offer valuing the biotech at about $10 billion after a weeks‑long bidding contest.
- Novo Nordisk exited the pursuit and said its unsolicited proposal, worth up to $9 billion, complied with antitrust law.
- Metsera said a transaction with Novo carried unacceptably high legal and regulatory risks, a key factor in the board’s decision.
- A shareholder vote is expected shortly to finalize the acquisition following the board’s acceptance of Pfizer’s offer.
- The deal underscores the race for next‑generation weight‑loss therapies in a market projected near $150 billion by the early 2030s as U.S. policymakers outline plans to lower drug prices.